Tags : PAH

Liquidia Reports Results of LIQ861 in P-III INSPIRE Trial in

Shots: The study involves assessing of LIQ861 in 109 patients divided in two groups of 65 prostacyclin-naive patients that were stable on ≤2 approved oral PAH therapies and 44 patients transitioning from Tyvaso (transition) with pAH The study resulted in median MLWHFQ score @transition and add on patients from 37 to 29 and 30 to […]Read More